Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2005-12-07
2010-02-02
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C536S023100
Reexamination Certificate
active
07655461
ABSTRACT:
The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.
REFERENCES:
patent: 5543291 (1996-08-01), Keyomarsi et al.
patent: 5788963 (1998-08-01), Murphy et al.
patent: 5846827 (1998-12-01), Celis et al.
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5973119 (1999-10-01), Coats et al.
patent: 6225443 (2001-05-01), DeMars et al.
patent: 6805861 (2004-10-01), Stauss
patent: 2002/0090362 (2002-07-01), Stauss
patent: 2002/0150891 (2002-10-01), Hood et al.
patent: 2003/0040617 (2003-02-01), Rosen et al.
patent: 2003/0143647 (2003-07-01), Finn et al.
patent: WO 96/12406 (1996-05-01), None
patent: WO 98/33450 (1998-08-01), None
patent: WO 99/60119 (1999-11-01), None
patent: WO 00/55351 (2000-09-01), None
Magarian-Blander et al. (Glycoconjugate Journal, vol. 13, pp. 749-756, 1996).
Burgess et al, Journal of Cell Biology vol. 111, pp. 2129-2138, Nov. 1990.
Lazar et al Molecular and Cellular Biology, vol. 8 No. 3, pp. 1247-1252, Mar. 1988.
Schwartz et al, Proc Natl Acad Sci, vol. 84, pp. 6408-6411, Sep. 1987.
Lin et al., Biochemistry, vol. 14, No. 8, pp. 1559-1563, 1975.
Attwood (Science 290: 471-473, 2000).
Skolnick et al. (Trends in Biotech. 18: 34-39, 2000).
WO2005113595, Dec. 2005, WOX.
Alajez et al. (Blood, vol. 105(12), pp. 4583-4589, Mar. 2005).
Aarnoudse et al., “TCR Reconstitution in Jurkat Reporter Cells Facilitates the Identification of Novel Tumor Antigens by CDNA Expression Cloning,”Int. J Cancer, 99(1): 7-13 (May 1, 2002).
Adams et al., “High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules,”Cancer Res, 61(12): 4750-4755 (Jun. 15, 2001).
Altschul et al., “Basic Local Alignment Search Tool,”J Mol Biol, 215(3): 403-410 (1990).
Avigan et al., “Immune Reconstitution Following High-Dose Chemotherapy With Stem Cell Rescue in Patients With Advanced Breast Cancer,”Bone Marrow Transplant, 26(2): 169-176 (Jul. 2, 2000).
Badou et al., “Mercuric Chloride-Induced Autoimmunity,”Current Protocols in Immunology, 3(Supplement 32): 15.15.1-15.15.18 (Aug. 1999).
Barnd et al., “Specific, Major Histocompatibility Complex-Unrestricted Recognition of Tumor-Associated Mucins by Human Cytotoxic T Cells,”Proc Natl Acad Sci U S A,, 86: 7159-7163 (Sep. 1989).
Barratt-Boyes, “Making the Most of Mucin: A Novel Target for Tumor Immunotherapy,”Cancer Immunology Immunotherapy, 43(3): 142-151 (1996).
Bensinger et al., “High-Dose Busulfan, Melphalan, Thiotepa and Peripheral Bolld Stem Cell Infusion for the Treatment of Metastatic Breast Cancer,”Bone Marrow Transplant, 19(12): 1183-1189 (Jun. 2, 1997).
Berard et al., “Cross-Priming of Naïve CD8 T Cells Against Melanoma Antigens Using Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells,”J. Exp. Med., 192(11): 1535-1543 (Dec. 4, 2000).
Berkner, “Development of Adenovirus Vectors for the Expression of Heterologous Genes,”BioTechniques, 6(7): 616-629 (Jul./Aug. 1988).
Boel et al., “BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes,”Immunity, 2: 167-175 (Feb. 1995).
Brenner et al., “Gene Marking to Determine Whether Autologous Marrow Infusion Restores Long-Term Haemopoiesis in Cancer Patients,”Lancet, 342(8880): 1134-1137 (Nov. 6, 1993).
Bubenik, “Tumour MHC Class I Downregulation and Immunotherapy,”Oncol Rep, 10(6): 2005-2008 (Dec. 2003).
Burchell et al., “A Short Sequence, Within the Amino Acid Tandem Repeat of a Cancer-Associated Mucin, Contains Immunodominant Epitopes,”Int J Cancer, 44(4): 691-696 (Oct. 15, 1989).
Callan et al., “Selection of T Cell Receptor Variable Gene-Encoded Amino Acids On The Third Binding Site Loop: A Factor Influencing Variable Chain Selection in a T Cell Response,”Eur J Immunol, 25(6): 1529-1534 (Jun. 1995).
Chung et al., “Functional Three-Domain Single-Chain T-Cell Receptors,”Proc Natl Acad Sci U S A, 91:12654-12658 (Dec. 1994).
Covini et al., “Immune Response to Cyclin B1 in Hepatocellular Carcinoma,”Hepatology, (PubMed Abstract ID 8985268), 25(1): 75-80 (Jan. 1997).
Crystal et al., “A Phase 1 Study, In Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung,”Human Gene Ther., 6(5): 643-666 (May 1995).
Crystal et al., “Evaluation of Repeat Administration of a Replication Deficient, Recombinant Adenovirus Containing the Normal Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Airways of Individulas with Cystic Fibrosis,”Human Gene Ther., 6(5): 667-703 (May 1995).
Davis et al., “Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone,”Blood, 92(4): 1184-1190 (Aug. 15, 1998).
Derby et al., “Two Internediate-Avidity Cytotoxic T Lymphocyte Clones With a Disparity Between Functional Avidity and MHC Tetramer Staining,”Int Immunol, 13(6): 817-824 (Jun. 2001).
Diefenbach et al., Rae1 and H60 Ligands of the NKG2D Receptor Stimulate Tumour Immunity,Nature, 413(6852): 165-171 (Sep. 13, 2001).
Disi et al., “HER-2
eu Oncogenic Protein: Issues in Vaccine Development,”Critical Reviews In Immunology, 18(1&2): 37-45 (1998).
Dong et al., “Prognostic Significance of Cyclin E Overexpression in Laryngela Squamous Cell Carcinomas,”Clinical Cancer Research, 6(11): 4253-4258 (Nov. 2000).
Dudley et al., “A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma,”J. Immunother, 25(3): 243-251 (May/Jun. 2002).
Dudley et al., “Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes,”Science, 298(5594): 850-854 (Oct. 25, 2002).
Dutta et al., “Cyclins as Markers of Tumor Proliferation: Immunocytochemical Studies in Breast Cancer,”Proc. Natl. Acad. Sci. USA, 92(12): 5386-5390 (Jun. 6, 1995).
Engel et al., “High-Efficiency Expression and Solubilization of Functional T Cell Antigen Receptor Heterodimers,”Science, 256(5061): 1318-1321 (May 29, 1992).
Eshhar et al., “The T-Body Approach: Potential For Cancer Immunotherapy,”Springer Semin Immunopathol, 18(2): 199-209 (1996).
Fernandez et al., “Dendritic Cells Directly Trigger NK Cell Functions: Cross-talk Relevant in Innate Anti-Tumor Immune Responses In Vivo,”Nat Med, 5(4): 405-411 (Apr. 1999).
Fontenot et al., “Biophysical Characterization of One-, Two-, and Three-Tandem Repeats of Human Mucin (muc-1) Protein Core,”Cancer Research, 53(22): 5386-5394 (Nov. 15, 1993).
Fontenot et al., “Structure of a Tumor Associated Antigen Containing a Tandemly Repeated Immunodominant Epitope,”Journal of Biomolecular Structure&Dynamics, 13(2): 245-260 (Oct. 1995).
Garcia et al., “An αβ Cell Receptor Structure at 2.5 A and Its Orientation in the TCR-MHC Complex,”Science274(5285): 209-219 (Oct. 11, 1996).
Gaugler et al., “Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes,”The Journal of Experimental Medicine, 179: 921-930 (Mar. 1994).
Gregoire et al., “Covalent Assembly of a Soluble T Cell Receptor-Peptide-major Histocompatibility Class I Complex,”Natl Acad Sci U S A, 93(14): 7184-7189 (Jul. 1996).
Hanenberg et al., “Colocalization of Retrovirus and Ta
Alajez Nehad M.
Alter Mark D.
Finn Olivera J.
Schmielau Jan
Helms Larry R.
Leydig , Voit & Mayer, Ltd.
Natarajan Meera
University of Pittsbugh — Of the Commonwealth System of H
LandOfFree
Therapeutic and diagnostic cloned MHC-unrestricted receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic cloned MHC-unrestricted receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic cloned MHC-unrestricted receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157651